# A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

> **NCT07544862** · — · NOT_YET_RECRUITING · sponsor: **Chengdu Kangnuoxing Biopharma,Inc.** · enrollment: 1000 (estimated)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

- **BIOLOGICAL:** Stapokibart

## Key facts

- **NCT ID:** NCT07544862
- **Lead sponsor:** Chengdu Kangnuoxing Biopharma,Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-12
- **Final completion:** 2028-02
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07544862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07544862, "A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07544862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*